Fathom Therapeutics
Summary active Updated Apr 28, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Investors
About
Fathom Therapeutics (formerly Atommap Corp.) is a New York-headquartered drug-discovery company using physics-based simulation and AI to design novel small molecules by modeling protein motion at atomic resolution 12. Its Microcosmos platform claims to accelerate protein-dynamics modeling by ~10,000x without compromising accuracy 1. Founders Huafeng Xu (CEO), Yujie Wu (CTO), and Jesus Izaguirre (Chief Computational Scientist) came together to translate decades of computational chemistry research into a lab-in-the-loop drug design engine; the company also operates a second office in Boston 12.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-27 | Series A | $47M | Sutter Hill Ventures | Chemistry, Alexandria Venture Investments, Empire State Development’s NY Ventures 12 |
What Investors Say
Keith Loebner, Sutter Hill Ventures: “He and the world-class team he’s assembled have demonstrated that their approach not only works, better than imagined” 1.
Ethan Kurzweil, Chemistry: “Fathom stood out as tackling one of the most ambitious, technically difficult challenges in biotech” 1.
What Founders Say
Huafeng Xu, CEO: “Current drug discovery efforts are limited by reliance on static structures of isolated proteins” 1.
Sources
-
PR Newswire, “Fathom Therapeutics, Formerly Atommap, Raises $47 Million in Oversubscribed Series A Financing to Translate Physics and AI-Enabled Small Molecule Design into Next-Generation Medicines,” April 27, 2026. https://www.prnewswire.com/news-releases/fathom-therapeutics-formerly-atommap-raises-47-million-in-oversubscribed-series-a-financing-to-translate-physics-and-ai-enabled-small-molecule-design-into-next-generation-medicines-302754272.html↩↩↩↩↩↩↩
-
AlleyWatch, “The AlleyWatch Startup Daily Funding Report: 4/28/2026,” April 28, 2026. https://www.alleywatch.com/2026/04/the-alleywatch-startup-daily-funding-report-4-28-2026/↩↩↩